Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050023/S204

Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Intica 7 VR-T 404634; I

Biotronik, Inc. · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONP050023/S204

What did the FDA approve?

On 2026-09-25, FDA recorded an approval decision on P050023/S204, a PMA supplement submitted by Biotronik, Inc. under the Normal 180 Day Track. The supplement reason is listed as Change Design/Components/Specifications/Material, and the device category is an implantable dual-chamber defibrillator (product code MRM, Cardiovascular specialty). The title field names Ilivia 7 VR-T DX 404624, Intica 7 VR-T DX 404633, Intica 5 VR-T DX 404688, Ilivia 7 VR-T 404625, Intica 7 VR-T 404634 and further truncated entries.

The recorded statement refers to the next generation of the Home Monitoring Service Center (HMSC), tying the supplement to that monitoring component rather than to a new approval of the entire device system. The source record does not specify which components, specifications or materials changed, what testing supported the change, or how the listed model numbers relate to the HMSC. No documents were included, so the supplement's scope and any conditions of approval remain unknown from this record.

FDA approval order statement

the next generation of the Home Monitoring Service Center (HMSC)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Sep 25, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P050023/S204
Regulatory pathway
PMA supplement
Product code
MRM
Decision code
APPR
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.

Product code
MRM
FDA device class
3

For the original device and its historical approval scope, see PMA P050023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P050023 · Original PMA

    TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD

  2. P050023/S204 received

    Application receipt date recorded by FDA.

  3. P050023/S211 · Related supplement

    PSW 2601.U, NEO 2601.U, Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, R

  4. P050023/S214 · Related supplement

    Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, Rivacor Sky HF-T QP, Riva

  5. P050023/S204 · FDA decision

    Normal 180 Day Track

  6. P050023/S213 · Related supplement

    Acticor Sky HF-T 481986; Rivacor Sky HF-T 481991; Rivacor Rise HF-T 482017; Rivacor Aura HF-T 482013; Acticor Sky HF-T Q

  7. P050023/S215 · Related supplement

    Ilivia 7 VR-T DX DF-1 ProMRI Ilivia 7 VR-T DF-1 ProMRI Ilivia 7 VR-T DF4 ProMRI Intica 7 VR-T DX DF-1 ProMRI Intica 7 VR

  8. P050023/S216 · Related supplement

    Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, Inlexa 7 VRT, Inlexa 7 VRT

Timeline entries are records held by MedtechLedger for P050023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050023

Explore the linked device profile

Other records with product code MRM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records